Wall Street brokerages expect that Catalent (NYSE:CTLT) will report earnings of $0.39 per share for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Catalent’s earnings, with the highest EPS estimate coming in at $0.46 and the lowest estimate coming in at $0.31. Catalent reported earnings of $0.38 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.6%. The company is expected to report its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that Catalent will report full-year earnings of $1.66 per share for the current year, with EPS estimates ranging from $1.50 to $1.73. For the next financial year, analysts anticipate that the company will post earnings of $1.88 per share, with EPS estimates ranging from $1.58 to $1.97. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, February 5th. The company reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business had revenue of $606.30 million for the quarter, compared to analyst estimates of $565.05 million. During the same quarter in the prior year, the firm posted $0.27 EPS. The business’s quarterly revenue was up 25.3% compared to the same quarter last year.
Catalent stock traded down $0.36 during mid-day trading on Friday, hitting $40.15. The company had a trading volume of 249,143 shares, compared to its average volume of 878,536. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66. Catalent has a 12-month low of $27.56 and a 12-month high of $47.87. The firm has a market cap of $5,332.75, a PE ratio of 29.67, a P/E/G ratio of 2.18 and a beta of 1.53.
In other Catalent news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the transaction, the senior vice president now owns 46,986 shares in the company, valued at approximately $1,964,014.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.70% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CTLT. Zions Bancorporation purchased a new position in Catalent in the 3rd quarter valued at $100,000. First Bank & Trust lifted its holdings in Catalent by 54.2% in the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after purchasing an additional 1,323 shares in the last quarter. CAPROCK Group Inc. purchased a new position in Catalent in the 4th quarter valued at $203,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in Catalent in the 4th quarter valued at $242,000. Finally, Trexquant Investment LP purchased a new position in Catalent in the 3rd quarter valued at $257,000. Institutional investors own 99.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/13/catalent-ctlt-expected-to-post-earnings-of-0-39-per-share.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.